APA (7th ed.) Citation

Adamik, J., Grant, A., Trujillo, D., Goyal, R. K., Ho, W., Chisamore, M., . . . Kassner, P. D. (2023). 704 Biological activity of FLX475, an oral CCR4 antagonist, as monotherapy and in combination with pembrolizumab in advanced cancer. Journal for immunotherapy of cancer, 11(Suppl 1), A799. https://doi.org/10.1136/jitc-2023-SITC2023.0704

Chicago Style (17th ed.) Citation

Adamik, Juraj, et al. "704 Biological Activity of FLX475, an Oral CCR4 Antagonist, as Monotherapy and in Combination with Pembrolizumab in Advanced Cancer." Journal for Immunotherapy of Cancer 11, no. Suppl 1 (2023): A799. https://doi.org/10.1136/jitc-2023-SITC2023.0704.

MLA (9th ed.) Citation

Adamik, Juraj, et al. "704 Biological Activity of FLX475, an Oral CCR4 Antagonist, as Monotherapy and in Combination with Pembrolizumab in Advanced Cancer." Journal for Immunotherapy of Cancer, vol. 11, no. Suppl 1, 2023, p. A799, https://doi.org/10.1136/jitc-2023-SITC2023.0704.